The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.
© 2025 TheOutpost.AI All rights reserved
Curated by THEOUTPOST
On Mon, 21 Apr, 4:01 PM UTC
3 Sources
[1]
Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025 - Aclarion (NASDAQ:ACONW), Aclarion (NASDAQ:ACON)
BROOMFIELD, Colo., April 23, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") ACON ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 12:30 PM ET. Brent Ness, Chief Executive Officer of Aclarion, will be presenting on the Company and recent value-driving initiatives. In conjunction with the event, Aclarion has published its updated investor presentation, which can be found on its website at https://investors.aclarion.com/. About Aclarion, Inc. Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company's current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contacts: Kirin M. Smith PCG Advisory, Inc. ksmith@pcgadvisory.com Jennie Kim SPRIG Consulting jennie@sprigconsulting.com ACONAclarion Inc$7.884.93%Stock Score Locked: Want to See it? Benzinga Rankings give you vital metrics on any stock - anytime. Reveal Full ScoreEdge RankingsMomentum-Growth13.99Quality-Value33.29Price TrendShortMediumLongOverviewACONWAclarion Inc$0.04510.22%Market News and Data brought to you by Benzinga APIs
[2]
Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis - Aclarion (NASDAQ:ACONW), Aclarion (NASDAQ:ACON)
Independent Cost-Effectiveness Analysis Concludes Nociscan is Effective and Less Costly Compared to Provocative DiscographyConclusions Illustrate Nociscan Saves $1,712 per Patient and Improves Surgical Success by 10% BROOMFIELD, Colo., April 21, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") ACON ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a peer-reviewed article in Clinicoeconomics and Outcomes Research titled "The Comparison of Cost-Effectiveness Between Magnetic Resonance Spectroscopy and Provocative Discography in the Identification of Chronic Low Back Pain Surgery Candidates." "Chronic low back pain is a complex problem that is complicated to diagnose," said Doug Beall, MD, Chief of Radiology Services, Clinical Radiology of Oklahoma and co-author. "I have a keen interest in advanced diagnostics and clinical decision support tools like Nociscan. The profound conclusions within this important paper will not only benefit surgical intervention, but also my non-surgical colleagues in Pain Management and Interventional Radiology. Our industry needs more evidence showcasing clinical and economic improvements when comparing alternatives, and our paper clearly illustrates the cost-effectiveness of Nociscan compared to provocative discography." ClinicoEconomics and Outcomes Research is a peer-reviewed healthcare journal focusing on covering the economic impact of health policy and health systems organization. The journal was established in 2009 and is published by Dove Medical Press. "We are pleased with the cost-effectiveness results illustrated in this important paper," said Ryan Bond, Chief Strategy Officer at Aclarion. "We believe the results demonstrating Nociscan's economic outperformance over provocative discography will be important to our physician customers and their patients, but will also speak clearly to the payer community, who are constantly challenged to reconcile the health outcomes achieved for the dollars they spend, in other words, the value in healthcare." Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain. To find a Nociscan center, view our site map here. For more information on Nociscan, please email: info@aclarion.com All organizations cited and/or quotes from individuals not part of Aclarion have reviewed and approved the contents herein. About Aclarion, Inc. Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company's current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contacts: Kirin M. Smith PCG Advisory, Inc. ksmith@pcgadvisory.com Jennie Kim SPRIG Consulting jennie@sprigconsulting.com ACONAclarion Inc$8.81-1.89%Stock Score Locked: Want to See it? Benzinga Rankings give you vital metrics on any stock - anytime. Reveal Full ScoreEdge RankingsMomentum-Growth13.92Quality-Value33.68Price TrendShortMediumLongOverviewACONWAclarion Inc$0.0453-%Market News and Data brought to you by Benzinga APIs
[3]
Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis By Investing.com
BROOMFIELD, Colo., April 21, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (Aclarion or the Company) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a peer-reviewed article in Clinicoeconomics and Outcomes Research titled "The Comparison of Cost-Effectiveness Between Magnetic Resonance Spectroscopy and Provocative Discography in the Identification of Chronic Low Back Pain Surgery Candidates. Chronic low back pain is a complex problem that is complicated to diagnose, said Doug Beall, MD, Chief of Radiology Services, Clinical Radiology of Oklahoma and co-author. I have a keen interest in advanced diagnostics and clinical decision support tools like Nociscan. The profound conclusions within this important paper will not only benefit surgical intervention, but also my non-surgical colleagues in Pain Management and Interventional Radiology. Our industry needs more evidence showcasing clinical and economic improvements when comparing alternatives, and our paper clearly illustrates the cost-effectiveness of Nociscan compared to provocative discography. ClinicoEconomics and Outcomes Research is a peer-reviewed healthcare journal focusing on covering the economic impact of health policy and health systems organization. The journal was established in 2009 and is published by Dove Medical Press. We are pleased with the cost-effectiveness results illustrated in this important paper, said Ryan Bond, Chief Strategy Officer at Aclarion. We believe the results demonstrating Nociscan's economic outperformance over provocative discography will be important to our physician customers and their patients, but will also speak clearly to the payer community, who are constantly challenged to reconcile the health outcomes achieved for the dollars they spend, in other words, the value in healthcare. Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain. To find a Nociscan center, view our site map here. For more information on Nociscan, please email: info@aclarion.com All organizations cited and/or quotes from individuals not part of Aclarion have reviewed and approved the contents herein. About Aclarion, Inc. Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as anticipates, believes and expects or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company's current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled Risk Factors in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Share
Share
Copy Link
Aclarion's Nociscan, an AI-powered diagnostic tool for chronic low back pain, demonstrates superior cost-effectiveness compared to traditional methods. The company releases updated investor information and announces a seminal cost-effectiveness analysis publication.
Aclarion, Inc. (NASDAQ: ACON, ACONW), a healthcare technology company, has developed Nociscan, an innovative diagnostic tool leveraging artificial intelligence to address the global issue of chronic low back pain (cLBP). With approximately 266 million people worldwide suffering from degenerative spine disease and low back pain, Nociscan aims to revolutionize the diagnosis and treatment of this pervasive condition 12.
Nociscan is the first evidence-supported SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine. The technology utilizes Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, and augmented intelligence algorithms to quantify chemical biomarkers associated with disc pain 13.
A peer-reviewed article published in Clinicoeconomics and Outcomes Research has revealed the cost-effectiveness of Nociscan compared to traditional provocative discography. The analysis concludes that Nociscan is not only effective but also less costly, saving $1,712 per patient and improving surgical success rates by 10% 2.
Dr. Doug Beall, Chief of Radiology Services at Clinical Radiology of Oklahoma and co-author of the study, emphasized the importance of this research: "Our industry needs more evidence showcasing clinical and economic improvements when comparing alternatives, and our paper clearly illustrates the cost-effectiveness of Nociscan compared to provocative discography" 2.
Ryan Bond, Chief Strategy Officer at Aclarion, highlighted the significance of these findings for both healthcare providers and payers: "We believe the results demonstrating Nociscan's economic outperformance over provocative discography will be important to our physician customers and their patients, but will also speak clearly to the payer community" 23.
Aclarion is positioning itself as a leader in the chronic low back pain diagnostic market. The company recently presented at the Planet MicroCap Showcase: VEGAS 2025, where CEO Brent Ness discussed recent value-driving initiatives 1.
In conjunction with this event, Aclarion has published an updated investor presentation, available on their website, showcasing the company's progress and future plans 1.
Nociscan operates through a cloud connection, receiving MRS data from MRI machines for each lumbar disc being evaluated. Proprietary signal processing techniques in the cloud extract and quantify chemical biomarkers associated with disc pain. This data is then processed through proprietary algorithms to indicate potential pain sources 123.
As Aclarion continues to develop and refine its AI-powered diagnostic tools, the company is poised to make significant strides in addressing the complex issue of chronic low back pain, potentially transforming patient care and treatment strategies in the field of spinal health.
Reference
Aclarion secures full funding for its CLARITY trial, aiming to validate Nociscan's ability to improve surgical outcomes for chronic low back pain patients using MR Spectroscopy and AI.
4 Sources
4 Sources
Several companies, including iCAD, SKYX, Acrivon Therapeutics, and Janover, have reported their second quarter 2024 financial results. While some companies showed growth, others faced challenges in revenue and net losses.
6 Sources
6 Sources
Transcarent and Accolade announce a significant milestone in their merger process, with the expiration of the Hart-Scott-Rodino waiting period. The merger aims to combine AI-powered healthcare solutions with advocacy and primary care services.
2 Sources
2 Sources
Ainos, Inc. unveils its innovative AI Nose technology and VELDONA therapeutics, aiming to revolutionize healthcare with AI-powered point-of-care testing and low-dose interferon treatments.
4 Sources
4 Sources
Transcarent announces acquisition of Accolade for $621 million, combining AI-powered healthcare services with personalized healthcare platforms to revolutionize the healthcare experience.
3 Sources
3 Sources
